Otsuka Pharmaceutical has agreed to acquire Astex Pharmaceuticals for approximately US $866 million in order to strengthen its cancer portfolio. Both Boards of Directors have unanimously approved ...

Astex Pharmaceuticals, Inc. has announced that clinical development of its lung cancer drug, amuvatinib (MP-470), has been discontinued. Amuvatinib is a multi-targeted tyronsine kinase inhibitor ...

American Funds Shrt-Term Tx-Exmpt Bd earns an Above Average Process Pillar rating. The largest contributor to the rating is its parent firm's excellent long-term risk-adjusted performance, as ...

CAMBRIDGE, United Kingdom, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small ...

The drugs targeting AKT include capivasertib, which was discovered following collaborative work by the ICR and partners Astex Pharmaceuticals and AstraZeneca and is currently in three major phase III ...

A great many scientists and clinicians have played important parts in the drug’s story, from the ICR and from partners including the pharmaceutical companies Astex and AstraZeneca, The Royal Marsden ...